Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
NCT03679676 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108
Last updated 2025-05-21
Summary
Food allergy (FA) is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children, 30% with multiple food allergies) and about 9% of adults. This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be a peanut. The total of participants in the clinical study will be 110, ages 4 to 55 years with a history of multiple food allergies of 2 to 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the Double-blind Placebo-controlled Food challenge (DBPCFC) at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.
Conditions
- Hypersensitivity
- Food Allergy
- Hypersensitivity, Food
- Peanut Hypersensitivity
- Peanut Allergy
Interventions
- DRUG
-
Omalizumab
Omalizumab is injected every 2 to 4 weeks
- DRUG
-
Dupilumab is injected every 2 weeks combination, or placebo.
- OTHER
-
Placebo
Placebo is injected every 2 to 4 weeks
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Food Allergy Research & Education
collaborator OTHER -
Harvard School of Public Health (HSPH)
collaborator OTHER - lead OTHER
Principal Investigators
-
Rebecca S Chinthrajah, M.D. · Sean N Parker Center for Allergy and Asthma Center at Stanford
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 4 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-02-05
- Primary Completion
- 2025-04-15
- Completion
- 2025-05-02
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
NCT01781637 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy
NCT02879006 ·Status: UNKNOWN ·Phase: PHASE2
-
Peanut Oral Immunotherapy in Children
NCT01867671 ·Status: COMPLETED ·Phase: PHASE2
-
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
NCT06369467 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
NCT03793608 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Omalizumab in the Skin of Food Allergy Patients
NCT06618963 ·Status: RECRUITING ·Phase: PHASE4
-
Baked Milk Oral Immunotherapy for Cow's Milk Allergy
NCT03462030 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
NCT05695261 ·Status: RECRUITING ·Phase: PHASE2
-
Omalizumab to Accelerate a Symptom-driven Multi-food OIT
NCT04045301 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
OIT and Xolair® (Omalizumab) in Cow's Milk Allergy
NCT01157117 ·Status: COMPLETED ·Phase: PHASE2
-
E-B-FAHF-2, Multi OIT and Xolair for Food Allergy
NCT06103656 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
NCT01084174 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Omalizumab in the Treatment of Peanut Allergy
NCT00949078 ·Status: COMPLETED ·Phase: PHASE2
-
Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels
NCT06934200 ·Status: RECRUITING ·Phase: PHASE2
-
A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
NCT07027163 ·Status: COMPLETED
-
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
NCT00382148 ·Status: COMPLETED ·Phase: PHASE2
-
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
NCT00932282 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy
NCT01897077 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Oral Immunotherapy for Peanut Allergy (PMIT)
NCT00597675 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of Xolair in Peanut Allergy
NCT00086606 ·Status: TERMINATED ·Phase: PHASE2
-
Oral Peanut Immunotherapy
NCT01324401 ·Status: COMPLETED ·Phase: NA
-
Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects
NCT03070561 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Dupilumab Therapy for EGIDs
NCT07257835 ·Status: RECRUITING
-
Efficacy of Tezepelumab in Peanut Oral Immunotherapy
NCT07015996 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
NCT01904604 ·Status: COMPLETED ·Phase: PHASE2